[go: up one dir, main page]

WO2016196285A1 - Therapies utilizing compounds to fibroblast growth factor receptor-3 (fgfr3) - Google Patents

Therapies utilizing compounds to fibroblast growth factor receptor-3 (fgfr3) Download PDF

Info

Publication number
WO2016196285A1
WO2016196285A1 PCT/US2016/034645 US2016034645W WO2016196285A1 WO 2016196285 A1 WO2016196285 A1 WO 2016196285A1 US 2016034645 W US2016034645 W US 2016034645W WO 2016196285 A1 WO2016196285 A1 WO 2016196285A1
Authority
WO
WIPO (PCT)
Prior art keywords
fgfr3
growth factor
factor receptor
fibroblast growth
therapies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/034645
Other languages
French (fr)
Inventor
Jan COSAERT
Dale L. Ludwig
Alan C. Rigby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunogen Inc
ImClone LLC
Original Assignee
Immunogen Inc
ImClone LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc, ImClone LLC filed Critical Immunogen Inc
Publication of WO2016196285A1 publication Critical patent/WO2016196285A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides therapies utilizing conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugate therapeutic uses are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The present invention is the use of these therapies in lung cancer, specifically those with a FGFR3-TACC gene fusion, bladder cancer, specifically those with a FGFR3-BAIAP2L1 gene fusion, and bladder cancer in combination with an anti-VEGFR2 antibody.
PCT/US2016/034645 2015-06-04 2016-05-27 Therapies utilizing compounds to fibroblast growth factor receptor-3 (fgfr3) Ceased WO2016196285A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562171007P 2015-06-04 2015-06-04
US62/171,007 2015-06-04

Publications (1)

Publication Number Publication Date
WO2016196285A1 true WO2016196285A1 (en) 2016-12-08

Family

ID=56137531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/034645 Ceased WO2016196285A1 (en) 2015-06-04 2016-05-27 Therapies utilizing compounds to fibroblast growth factor receptor-3 (fgfr3)

Country Status (2)

Country Link
TW (1) TW201711702A (en)
WO (1) WO2016196285A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4276112A4 (en) * 2021-01-05 2025-03-12 Aimed Bio Inc. ANTI-FGFR3 ANTIBODIES AND USE THEREOF

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2003075840A2 (en) 2002-03-04 2003-09-18 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
WO2005012359A2 (en) 2003-08-01 2005-02-10 Genentech, Inc. Anti-vegf antibodies
USRE39151E1 (en) 2000-08-18 2006-06-27 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
US7411063B2 (en) 2005-11-08 2008-08-12 Immunogen, Inc. Process for preparation of maytansinol
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
US7598375B2 (en) 2005-08-09 2009-10-06 Millenium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
US20100098696A1 (en) * 2008-10-20 2010-04-22 Haijun Sun Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
US20110003969A1 (en) 2009-06-03 2011-01-06 Immunogen Inc. Conjugation methods
US20110166319A1 (en) 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US8163888B2 (en) 2003-10-10 2012-04-24 Immunogen, Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
US8236319B2 (en) 2008-04-30 2012-08-07 Immunogen, Inc. Cross-linkers and their uses
US20120253021A1 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
US20120259100A1 (en) 2011-03-29 2012-10-11 Immunogen, Inc. Process for manufacturing conjugates of improved homogeneity
WO2013083817A1 (en) * 2011-12-08 2013-06-13 Biotest Ag Uses of immunoconjugates targeting cd138
WO2014193229A2 (en) * 2013-05-27 2014-12-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Novel translocations in lung cancer
WO2015094900A1 (en) * 2013-12-18 2015-06-25 Imclone Llc Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39151E1 (en) 2000-08-18 2006-06-27 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7368565B2 (en) 2001-05-31 2008-05-06 Immunogen Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2003075840A2 (en) 2002-03-04 2003-09-18 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2005012359A2 (en) 2003-08-01 2005-02-10 Genentech, Inc. Anti-vegf antibodies
US8163888B2 (en) 2003-10-10 2012-04-24 Immunogen, Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
US20110166319A1 (en) 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7598375B2 (en) 2005-08-09 2009-10-06 Millenium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
US8383122B2 (en) 2005-08-24 2013-02-26 Immunogen, Inc. Process for preparing purified drug conjugates
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
US7411063B2 (en) 2005-11-08 2008-08-12 Immunogen, Inc. Process for preparation of maytansinol
US8236319B2 (en) 2008-04-30 2012-08-07 Immunogen, Inc. Cross-linkers and their uses
US20100098696A1 (en) * 2008-10-20 2010-04-22 Haijun Sun Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
US8043618B2 (en) 2008-10-20 2011-10-25 ImClone, LLC Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment
US20110003969A1 (en) 2009-06-03 2011-01-06 Immunogen Inc. Conjugation methods
US20120259100A1 (en) 2011-03-29 2012-10-11 Immunogen, Inc. Process for manufacturing conjugates of improved homogeneity
US20120253021A1 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
WO2013083817A1 (en) * 2011-12-08 2013-06-13 Biotest Ag Uses of immunoconjugates targeting cd138
WO2014193229A2 (en) * 2013-05-27 2014-12-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Novel translocations in lung cancer
WO2015094900A1 (en) * 2013-12-18 2015-06-25 Imclone Llc Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BURDON ET AL.: "Laboratory Techniques in Biochemistry and Molecular Biology", vol. 13, ELSEVIER SCIENCE PUBLISHERS
CAMPBELL: "Monoclonal Antibody Technology, The Production and Characterization of Rodent and Human Hybridomas", 1984
CHOTHIA ET AL., J MOL BIOL., vol. 196, 1987, pages 901 - 917
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883
COLIGAN, J. ET AL.: "Current Protocols in Immunology", 2007, WILEY & SONS
HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281
JAIN NARESHKUMAR ET AL: "Current ADC Linker Chemistry", PHARMACEUTICAL RESEARCH, SPRINGER NEW YORK LLC, US, vol. 32, no. 11, 11 March 2015 (2015-03-11), pages 3526 - 3540, XP035553874, ISSN: 0724-8741, [retrieved on 20150311], DOI: 10.1007/S11095-015-1657-7 *
KABAT: "Sequences of Proteins of Immunological Interest, Fifth Edition,", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES ( NIH PUBLICATION NO. 91-3242 )
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497
LOHRISCH ET AL., SEMINARS IN ONCOLOGY, vol. 28, no. 6, 2001, pages 3 - 11
PREWETT M. ET AL., CANCER RES., vol. 59, 1999, pages 5209 - 5218
RITTER, A.: "Antibody-Drug Conjugates, Looking Ahead to an Emerging Class of Biotherapeutic", PHARMACEUTICAL TECHNOLOGY, January 2012 (2012-01-01), pages 42 - 47
SAMBROOK, J. ET AL.: "Molecular Cloning: A Laboratory Manual, 2nd ed.,", 1989, COLD SPRING HARBOR LABORATORY PRESS
WITTE L. ET AL., CANCER METASTASIS REV., vol. 17, 1998, pages 155 - 161

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4276112A4 (en) * 2021-01-05 2025-03-12 Aimed Bio Inc. ANTI-FGFR3 ANTIBODIES AND USE THEREOF

Also Published As

Publication number Publication date
TW201711702A (en) 2017-04-01

Similar Documents

Publication Publication Date Title
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MX347893B (en) Human antibody drug conjugates against tissue factor.
PH12019502545A1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
MX2019010804A (en) Benzazepine compounds, conjugates, and uses thereof.
EP4233909A3 (en) Anti-cmet antibody drug conjugates and methods for their use
AU2015219495B2 (en) Disease therapy by inducing immune response to Trop-2 expressing cells
HK1224179A1 (en) Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses
NZ756730A (en) Combination therapy with an anti-axl antibody-drug conjugate
SG11201807936VA (en) Cell injury inducing therapeutic drug for use in cancer therapy
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
MX2021008334A (en) Stability-modulating linkers for use with antibody drug conjugates.
EP4556029A3 (en) Radiopharmaceutical conjugate
MY169147A (en) Drug-protein conjugates
PH12012501836A1 (en) Pyrrolobenzodiazepines and conjugates thereof
HK1208629A1 (en) Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency
WO2017062619A3 (en) Combination therapy for the treatment of cancer
HK1201462A1 (en) Methods of treating cancer
EP3895725A3 (en) A method for treating tumor by using recombinant interferon with changed spatial configuration
MX2021015533A (en) Anti-mesothelin antibodies and immunoconjugates thereof.
WO2017062615A3 (en) Combination therapy for the treatment of cancer
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
WO2012075490A3 (en) Anti-podoplanin antibodies and methods of use
WO2011056566A3 (en) Compounds and methods for treatment of cancer
WO2016196285A1 (en) Therapies utilizing compounds to fibroblast growth factor receptor-3 (fgfr3)
WO2019070161A3 (en) Articles and methods directed to personalized therapy of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16730572

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16730572

Country of ref document: EP

Kind code of ref document: A1